Argos Therapeutics, Inc. (ARGS) will report its next earnings on May 11 BMO. The company reported the earnings of $-0.35/Share in the last quarter where the estimated EPS by analysts was $-0.34/share. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -2.9%.
Many analysts are providing their Estimated Earnings analysis for Argos Therapeutics, Inc. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.33/share. These analysts have also projected a Low Estimate of $-0.35/share and a High Estimate of $-0.31/share.
In case of Revenue Estimates, 120000 analysts have provided their consensus Average Revenue Estimates for Argos Therapeutics, Inc. as 2000. According to these analysts, the Low Revenue Estimate for Argos Therapeutics, Inc. is 100 Million and the High Revenue Estimate is 150 Million. The company had Year Ago Sales of 146 Million.
Some buy side analysts are also providing their Analysis on Argos Therapeutics, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 4 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Argos Therapeutics, Inc. might touch $2 high while the Average Price Target and Low price Target is $1.6 and $1.2 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Argos Therapeutics, Inc. got Downgrade on 22-Feb-17 where investment firm JMP Securities Downgrade the stock from Mkt Outperform to Mkt Perform.
Argos Therapeutics, Inc. closed its last trading session at $0.39 with the gain of 53.39%. The Market Capitalization of the company stands at 24.76 Million. The Company has 52-week high of $13.46 and 52-week low of $0.31. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 26.29% where SMA50 and SMA200 are -64.99% and -85.54% respectively. The Company Touched its 52-Week High on 06/07/16 and 52-Week Low on 03/29/17.
The Relative Volume of the company is 13.2 and Average Volume (3 months) is 947.21 million. Argos Therapeutics, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -67.3%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is -96.3%.
While looking at the Stock’s Performance, Argos Therapeutics, Inc. currently shows a Weekly Performance of 75.92%, where Monthly Performance is -29.42%, Quarterly performance is -87.63%, 6 Months performance is -87.02% and yearly performance percentage is -94.39%. Year to Date performance value (YTD perf) value is -87.76%. The Stock currently has a Weekly Volatility of 26.36% and Monthly Volatility of 24.83%.